BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Synta Pharmaceuticals Announces First Patients Treated in Two ALK Positive Lung Cancer Trials


8/2/2012 10:43:30 AM

LEXINGTON, Mass.--(BUSINESS WIRE)--Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that the first patients have been treated in two trials evaluating the company’s lead drug candidate, ganetespib, a selective and potent Hsp90 inhibitor, in patients with non-small cell lung cancer (NSCLC) whose tumors show rearrangement of the anaplastic lymphoma kinase gene (ALK+). The company-sponsored CHIARA trial (CHaperone Inhibition in Alk Rearranged lung cAncer) is evaluating ganetespib monotherapy administration in up to 110 patients from centers in the U.S., Canada, Europe, and Asia. A trial sponsored by and conducted at the Memorial Sloan-Kettering Cancer Center in New York City is evaluating the combination of ganetespib and crizotinib (Xalkori®) in up to 55 patients. Both trials are enrolling patients who have not been previously treated with a direct ALK inhibitor, such as crizotinib.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES